Methods Compared Classifying Intensity of Soil-Transmitted Helminth Infections
|
By LabMedica International staff writers Posted on 23 Jul 2020 |

Image: The FECPAKG2 is an internet connected, image based diagnostic platform scientifically validated to conduct fecal egg count (FEC) tests (Photo courtesy of Techion).
Soil-transmitted helminths (Ascaris lumbricoides, Trichuris trichiura) and the hookworms, Necator americanus and Ancylostoma duodenale affect one quarter of the world population, and are responsible for the loss of more than three million disability-adjusted life years (DALYs).
There are a variety of novel microscopy and DNA-based methods to identify soil-transmitted helminths, but it remains unclear whether applying current World Health Organization (WHO) thresholds on to these methods allows for a reliable classification of moderate-to-heavy intensity (M&HI) infections.
An international team of scientists led by those at Ghent University (Merelbeke, Belgium) defined method-specific thresholds and verified whether they increased the correct classification of M&HI infections in a multi-countries study. They evaluated both WHO and method-specific thresholds for classifying the M&HI infections for novel microscopic methods: McMaster egg counting technique, FECPAKG2 (Techion, Aberystwyth, UK), and Mini-FLOTAC (Federico II University of Naples, Naples, Italy) and DNA-based (qPCR) diagnostic methods (Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands). The samples were also analyzed by Kato-Katz method as the reference method.
The team applied the WHO thresholds, the new microscopic methods mainly misclassified M&HI as low intensity, and to a lesser extent low intensity infection as M&HI. For FECPAKG2, applying the method-specific thresholds significantly improved the agreement for Ascaris (moderate → substantial), Trichuris and hookworms (fair → moderate). For Mini-FLOTAC, a significantly improved agreement was observed for hookworms only (fair → moderate). For the other STHs, the agreement was almost perfect and remained unchanged. For McMaster, the method-specific thresholds revealed a fair to a substantial agreement, but did not significantly improve the agreement. For qPCR, the method-specific thresholds based on genome equivalents per mL of DNA moderately agreed with the reference method for hookworms and Trichuris infections. For Ascaris, there was a substantial agreement.
The authors concluded that their results indicated that method-specific thresholds improved the classification of M&HI infections, but they stressed that validation studies are required before they can be recommended for general use in assessing M&HI infections in programmatic settings. The study also highlights the need (i) to agree on an absolute universal unit for qPCR, (ii) to align the evaluation of diagnostic methods with current STH program goals, and (iii) to define minimal and ideal (optimistic) criteria that diagnostic methods should meet in order to assess M&HI infections reliably. The study was published on July 2, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Ghent University
Techion
Federico II University of Naples
Elisabeth-Tweesteden Hospital
There are a variety of novel microscopy and DNA-based methods to identify soil-transmitted helminths, but it remains unclear whether applying current World Health Organization (WHO) thresholds on to these methods allows for a reliable classification of moderate-to-heavy intensity (M&HI) infections.
An international team of scientists led by those at Ghent University (Merelbeke, Belgium) defined method-specific thresholds and verified whether they increased the correct classification of M&HI infections in a multi-countries study. They evaluated both WHO and method-specific thresholds for classifying the M&HI infections for novel microscopic methods: McMaster egg counting technique, FECPAKG2 (Techion, Aberystwyth, UK), and Mini-FLOTAC (Federico II University of Naples, Naples, Italy) and DNA-based (qPCR) diagnostic methods (Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands). The samples were also analyzed by Kato-Katz method as the reference method.
The team applied the WHO thresholds, the new microscopic methods mainly misclassified M&HI as low intensity, and to a lesser extent low intensity infection as M&HI. For FECPAKG2, applying the method-specific thresholds significantly improved the agreement for Ascaris (moderate → substantial), Trichuris and hookworms (fair → moderate). For Mini-FLOTAC, a significantly improved agreement was observed for hookworms only (fair → moderate). For the other STHs, the agreement was almost perfect and remained unchanged. For McMaster, the method-specific thresholds revealed a fair to a substantial agreement, but did not significantly improve the agreement. For qPCR, the method-specific thresholds based on genome equivalents per mL of DNA moderately agreed with the reference method for hookworms and Trichuris infections. For Ascaris, there was a substantial agreement.
The authors concluded that their results indicated that method-specific thresholds improved the classification of M&HI infections, but they stressed that validation studies are required before they can be recommended for general use in assessing M&HI infections in programmatic settings. The study also highlights the need (i) to agree on an absolute universal unit for qPCR, (ii) to align the evaluation of diagnostic methods with current STH program goals, and (iii) to define minimal and ideal (optimistic) criteria that diagnostic methods should meet in order to assess M&HI infections reliably. The study was published on July 2, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Ghent University
Techion
Federico II University of Naples
Elisabeth-Tweesteden Hospital
Latest Technology News
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Channels
Clinical Chemistry
view channel
Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air
Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more
Head-to-Head Study Compares Blood Tests for Early Alzheimer’s Disease Detection
Accurate, scalable diagnostics are becoming increasingly important as disease-modifying therapies reshape Alzheimer’s disease care, yet many patients still rely on invasive cerebrospinal fluid sampling... Read more
Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy
Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read moreMolecular Diagnostics
view channel
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
Prenatal genetic testing is increasingly used to identify potential neurodevelopmental conditions, but results often include variants of uncertain significance that clinicians cannot confidently classify.... Read more
New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read morePathology
view channel
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read more
AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
Clinical decisions often rely on chronological age, yet organs can age biologically at different rates that remain hard to assess. Noninvasive detection of organ-specific aging could support disease monitoring... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more







